Investigating LTX-315 as a Therapeutic Peptide: Antimicrobial Activity on Clinical Bacterial Isolates.

Khanh HT, Ngoc-Ngan TH, Phuong HBT, The AL, Nhiet NB, Bui LM, Xuan HL, Minh DN

Journal of peptide science : an official publication of the European Peptide Society1 Nov 2026

PMID42843983DOI10.1002/psc.70137PepBankPUB-42843983

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

4 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In bacterial assays, LTX‑315 had MICs of 8-32 μM against reference strains.
In plain wordsIn lab tests, LTX‑315 inhibited reference bacteria at 8-32 μM.
Peptide
LTX-315
Outcome
Not applicableReference strain MIC
Study
bacterian: not reported in source
reference strains and multidrug-resistant clinical bacterial isolates
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Measurements
MIC
8 to 32 μM
reference strains
Source sentences
Summary
LTX-315 exhibited broad-spectrum antibacterial activity, with MICs of 8-32 μM against reference strains and as low as 4 μM against several MDR clinical isolates, whereas chloramphenicol and kanamycin were ineffective.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we evaluated the antibacterial activity of LTX-315, a synthetic cationic 9-mer peptide originally developed as an oncolytic agent, against six ATCC reference strains and six clinical isolates,
Report a problemFND-4284398301
02LabIn vitro (cells)Activity measurement
In bacterial assays, LTX‑315 had MICs as low as 4 μM against several multidrug-resistant clinical isolates.
In plain wordsIn lab tests, LTX‑315 inhibited several drug-resistant clinical isolates at concentrations as low as 4 μM.
Peptide
LTX-315
Outcome
Not applicableClinical isolate MIC
Study
bacterian: not reported in source
reference strains and multidrug-resistant clinical bacterial isolates
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Measurements
MIC
4 μM
several MDR clinical isolates, as low as
Source sentences
Summary
LTX-315 exhibited broad-spectrum antibacterial activity, with MICs of 8-32 μM against reference strains and as low as 4 μM against several MDR clinical isolates, whereas chloramphenicol and kanamycin were ineffective.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we evaluated the antibacterial activity of LTX-315, a synthetic cationic 9-mer peptide originally developed as an oncolytic agent, against six ATCC reference strains and six clinical isolates,
Report a problemFND-4284398302
03LabIn vitro (cells)Activity measurement
In bacterial assays, LTX‑315 inhibited several multidrug-resistant clinical isolates whereas chloramphenicol was ineffective.
In plain wordsIn lab tests, LTX‑315 inhibited several drug-resistant clinical isolates whereas chloramphenicol was ineffective.
Peptide
LTX-315
Outcome
IncreaseActivity versus chloramphenicol
Study
bacterian: not reported in source
reference strains and multidrug-resistant clinical bacterial isolates
Comparator
chloramphenicol
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Source sentences
Summary
LTX-315 exhibited broad-spectrum antibacterial activity, with MICs of 8-32 μM against reference strains and as low as 4 μM against several MDR clinical isolates, whereas chloramphenicol and kanamycin were ineffective.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we evaluated the antibacterial activity of LTX-315, a synthetic cationic 9-mer peptide originally developed as an oncolytic agent, against six ATCC reference strains and six clinical isolates,
Report a problemFND-4284398303
04LabIn vitro (cells)Activity measurement
In bacterial assays, LTX‑315 inhibited several multidrug-resistant clinical isolates whereas kanamycin was ineffective.
In plain wordsIn lab tests, LTX‑315 inhibited several drug-resistant clinical isolates whereas kanamycin was ineffective.
Peptide
LTX-315
Outcome
IncreaseActivity versus kanamycin
Study
bacterian: not reported in source
reference strains and multidrug-resistant clinical bacterial isolates
Comparator
kanamycin
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Source sentences
Summary
LTX-315 exhibited broad-spectrum antibacterial activity, with MICs of 8-32 μM against reference strains and as low as 4 μM against several MDR clinical isolates, whereas chloramphenicol and kanamycin were ineffective.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we evaluated the antibacterial activity of LTX-315, a synthetic cationic 9-mer peptide originally developed as an oncolytic agent, against six ATCC reference strains and six clinical isolates,
Report a problemFND-4284398304

Studies that did not test the peptide alone6

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

05LabNot a test of LTX-315 aloneIn vitro (cells)Activity measurement
In disk diffusion assays, LTX‑315 showed synergistic interactions with aminoglycosides.
In plain wordsIn lab tests, LTX‑315 showed synergy with aminoglycoside antibiotics.
Peptide
LTX-315
Outcome
Not applicableAminoglycoside synergy
Study
bacterian: not reported in source
reference strains and multidrug-resistant clinical bacterial isolates
Outcome group
Infection and antimicrobial activity · Infection
Source sentences
Summary
Double-disk diffusion assays indicated synergistic interactions with aminoglycosides, chloramphenicol, and vancomycin, and checkerboard assays confirmed synergy-to-additivity interactions with gentamicin and vancomycin against S. aureus (FICI 0.38-0.75), yielding fourfold to 16-fold reductions in antibiotic dose.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we evaluated the antibacterial activity of LTX-315, a synthetic cationic 9-mer peptide originally developed as an oncolytic agent, against six ATCC reference strains and six clinical isolates,
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4284398305
06LabNot a test of LTX-315 aloneIn vitro (cells)Activity measurement
In disk diffusion assays, LTX‑315 showed synergistic interactions with chloramphenicol.
In plain wordsIn lab tests, LTX‑315 showed synergy with chloramphenicol.
Peptide
LTX-315
Outcome
Not applicableChloramphenicol synergy
Study
bacterian: not reported in source
reference strains and multidrug-resistant clinical bacterial isolates
Outcome group
Infection and antimicrobial activity · Infection
Source sentences
Summary
Double-disk diffusion assays indicated synergistic interactions with aminoglycosides, chloramphenicol, and vancomycin, and checkerboard assays confirmed synergy-to-additivity interactions with gentamicin and vancomycin against S. aureus (FICI 0.38-0.75), yielding fourfold to 16-fold reductions in antibiotic dose.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we evaluated the antibacterial activity of LTX-315, a synthetic cationic 9-mer peptide originally developed as an oncolytic agent, against six ATCC reference strains and six clinical isolates,
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4284398306
07LabNot a test of LTX-315 aloneIn vitro (cells)Activity measurement
In disk diffusion assays, LTX‑315 showed synergistic interactions with vancomycin.
In plain wordsIn lab tests, LTX‑315 showed synergy with vancomycin.
Peptide
LTX-315
Outcome
Not applicableVancomycin synergy
Study
bacterian: not reported in source
reference strains and multidrug-resistant clinical bacterial isolates
Outcome group
Infection and antimicrobial activity · Infection
Source sentences
Summary
Double-disk diffusion assays indicated synergistic interactions with aminoglycosides, chloramphenicol, and vancomycin, and checkerboard assays confirmed synergy-to-additivity interactions with gentamicin and vancomycin against S. aureus (FICI 0.38-0.75), yielding fourfold to 16-fold reductions in antibiotic dose.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we evaluated the antibacterial activity of LTX-315, a synthetic cationic 9-mer peptide originally developed as an oncolytic agent, against six ATCC reference strains and six clinical isolates,
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4284398307
08LabNot a test of LTX-315 aloneIn vitro (cells)Activity measurement
In checkerboard assays against S. aureus, LTX‑315 with gentamicin showed synergy-to-additivity interactions.
In plain wordsIn lab tests against S. aureus, LTX‑315 with gentamicin showed synergistic to additive interactions.
Peptide
LTX-315
Outcome
Not applicableGentamicin checkerboard interaction
Study
Staphylococcus aureusn: not reported in source
reference strains and multidrug-resistant clinical bacterial isolates
Outcome group
Infection and antimicrobial activity · Infection
Measurements
FICI range
0.38 to 0.75 unitless
gentamicin and vancomycin checkerboard interactions against S. aureus
Source sentences
Summary
Double-disk diffusion assays indicated synergistic interactions with aminoglycosides, chloramphenicol, and vancomycin, and checkerboard assays confirmed synergy-to-additivity interactions with gentamicin and vancomycin against S. aureus (FICI 0.38-0.75), yielding fourfold to 16-fold reductions in antibiotic dose.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we evaluated the antibacterial activity of LTX-315, a synthetic cationic 9-mer peptide originally developed as an oncolytic agent, against six ATCC reference strains and six clinical isolates,
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4284398308
09LabNot a test of LTX-315 aloneIn vitro (cells)Activity measurement
In checkerboard assays against S. aureus, LTX‑315 with vancomycin showed synergy-to-additivity interactions.
In plain wordsIn lab tests against S. aureus, LTX‑315 with vancomycin showed synergistic to additive interactions.
Peptide
LTX-315
Outcome
Not applicableVancomycin checkerboard interaction
Study
Staphylococcus aureusn: not reported in source
reference strains and multidrug-resistant clinical bacterial isolates
Outcome group
Infection and antimicrobial activity · Infection
Measurements
FICI range
0.38 to 0.75 unitless
gentamicin and vancomycin checkerboard interactions against S. aureus
Source sentences
Summary
Double-disk diffusion assays indicated synergistic interactions with aminoglycosides, chloramphenicol, and vancomycin, and checkerboard assays confirmed synergy-to-additivity interactions with gentamicin and vancomycin against S. aureus (FICI 0.38-0.75), yielding fourfold to 16-fold reductions in antibiotic dose.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we evaluated the antibacterial activity of LTX-315, a synthetic cationic 9-mer peptide originally developed as an oncolytic agent, against six ATCC reference strains and six clinical isolates,
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4284398309
10LabNot a test of LTX-315 aloneIn vitro (cells)Activity measurement
In S. aureus checkerboard assays, combinations of LTX‑315 with gentamicin and vancomycin yielded fourfold to 16-fold antibiotic dose reductions.
In plain wordsIn lab tests against S. aureus, LTX‑315 combinations reduced the required antibiotic dose fourfold to 16-fold.
Peptide
LTX-315
Outcome
DecreaseAntibiotic dose reduction
Study
Staphylococcus aureusn: not reported in source
reference strains and multidrug-resistant clinical bacterial isolates
Outcome group
Infection and antimicrobial activity · Infection
Measurements
Antibiotic dose reduction
4 to 16 fold
LTX-315 combinations with gentamicin and vancomycin against S. aureus
Source sentences
Summary
Double-disk diffusion assays indicated synergistic interactions with aminoglycosides, chloramphenicol, and vancomycin, and checkerboard assays confirmed synergy-to-additivity interactions with gentamicin and vancomycin against S. aureus (FICI 0.38-0.75), yielding fourfold to 16-fold reductions in antibiotic dose.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we evaluated the antibacterial activity of LTX-315, a synthetic cationic 9-mer peptide originally developed as an oncolytic agent, against six ATCC reference strains and six clinical isolates,
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-4284398310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.